Comprehensive Safety Exposure-Response Analysis to Support Ritlecitinib Dose Selection

The study evaluated the safety profile of ritlecitinib, a kinase inhibitor for treating alopecia areata, through a comprehensive safety exposure-response analysis involving 1,744 subjects. The analysis found no ritlecitinib-induced QTc prolongation and minimal changes in lymphocyte counts, with a low incidence of Grade 3/4 lymphopenia. The study supported a 50 mg non-loading dose regimen for both adults and adolescents, showing a favorable benefit-risk profile. The findings indicated that adverse events were more related to baseline characteristics than drug exposure, and the safety profile was consistent across different patient subgroups. The results were accepted by regulatory agencies, including the FDA, supporting the dose selection without the need for a TQT study.